यूरोपीय संघ -
आइसलैंडी -
EMA (European Medicines Agency)
efmody
diurnal europe b.v. - hýdrókortisón - adrenal hyperplasia, congenital - barksterar til almennrar notkunar - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
mydrane stungulyf, lausn 0,2 mg/ml + 3,1 mg/ml + 10 mg/ml
laboratoires thea* - lidocainum hýdróklóríð; phenylephrinum hýdróklóríð; tropicamidum inn - stungulyf, lausn - 0,2 mg/ml + 3,1 mg/ml + 10 mg/ml
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
duokopt (joz) augndropar, lausn 20 mg/ml + 5 mg/ml
laboratoires thea s.a.s. - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml + 5 mg/ml
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
abstral tungurótartafla 800 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 800 míkróg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 50 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 50 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
abstral tungurótartafla 600 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 600 míkróg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 5 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 5 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 25 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 25 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
abstral tungurótartafla 400 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 400 míkróg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 200 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 200 mg